All In Biotech

Drug Trial Radar · NCT05194995

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Feb 17, 2022

Primary completion

Apr 30, 2025

Study completion Dec 2026

Sponsor

Lead sponsor
Allist Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jan 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of JAB-21822 in combination with cetuximab in patients with advanced colorectal cancer,advanced small intestine cancer and advanced appendiceal cancer with KRAS p.G12C mutation.

Conditions

  • Advanced Colorectal Cancer
  • Small Intestinal Cancer
  • Appendiceal Cancer

Interventions

  • JAB-21822Drug

    JAB-21822 administered orally as a tablet.

  • CetuximabDrug

    Cetuximab administered as an intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation phase: Number of participants with dose-limiting toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
  2. Dose Expansion phase: Overall response rate (ORR)Time frame: Up to 4 years - from baseline to RECIST confirmed Progressive Disease

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Research site31

    Beijing, Beijing Municipality, China

  • Research site01

    Beijing, Beijing Municipality, China

  • Research site02

    Beijing, Beijing Municipality, China

  • Research site12

    Beijing, Beijing Municipality, China

  • Research site13

    Nanning, Guangxi, China

  • Research site06

    Harbin, Heilongjiang, China

  • Research site05

    Zhengzhou, Henan, China

  • Research site07

    Zhengzhou, Henan, China

  • Research site18

    Wuhan, Hubei, China

  • Research site11

    Changsha, Hunan, China

  • Research site29

    Changsha, Hunan, China

  • Research site09

    Nanjing, Jiangsu, China

  • Research site08

    Nanchang, Jiangxi, China

  • Research site16

    Linyi, Shandong, China

  • Research site28

    Shanghai, Shanghai Municipality, China

  • Research site23

    Xi’an, Shanxi, China

  • Research site19

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.